Comparison of Fibrinogen Concentrate and Cryoprecipitate in Pediatric Cardiac Surgery Patients

University of Virginia

Status and phase: Completed; Phase 4

Conditions: Pediatric HD; Bleeding

Treatments: Drug: Fibrinogen; Drug: Cryoprecipitate

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT04376762

HSR180028-FC vs Cryo

Details and patient eligibility

About

The aim of the current pilot study proposal is to compare the use of the purified human fibrinogen concentrate (Fibryga®, Octapharma USA) to cryoprecipitate for the treatment of cardiopulmonary bypass (CPB)-associated bleeding in pediatric cardiac patients in whom fibrinogen supplementation is indicated.

The investigators' hypothesis is that fibrinogen concentrate will be as effective as cryoprecipitate in achieving adequate hemostasis after separation from CPB in pediatric cardiac surgery patients.

Study Design: this will be a single-center, prospective, randomized, active-control study in pediatric (24 months of age or younger) patients undergoing elective cardiac surgery with CPB (n=30) in-whom fibrinogen supplementation after separation from CPB is indicated, based on the presence of clinically-significant bleeding and documentation of low fibrinogen level on viscoelastic point-of-care testing (MCF < 10 mm on the FIBTEM assay of ROTEM). Informed consent will be obtained from a parent or a legal guardian prior to surgery and anesthesia. Once the need for fibrinogen supplementation is confirmed, study participants will be randomized into one of two treatment groups (n=15 in each group):

1. Cryoprecipitate group (dose: 10 ml/kg; active control group) or
2. Fibrinogen Concentrate group (dose: 70 mg/kg; intervention group). There will be no placebo group since withholding treatment is neither consistent with standard of care nor acceptable ethically. No other aspects of care will be modified. In the event that an additional dose of fibrinogen supplementation is required (bleeding with documented hypofibrinogenemia) cryoprecipitate will be administered to all study subjects (including those who received FC).

The results of this study will be used for publication as well as the first stage towards a significantly larger randomized multi-center trial (see below).

Based on the results of this pilot study the investigators plan to conduct a large multi-center, randomized active-control non-inferiority trial in the future, comparing the use of FC to cryoprecipitate in a much larger cohort of pediatric patients undergoing cardiac surgery with CPB. Ultimately, the results of this trial are likely to improve the care of pediatric cardiac surgical patients experiencing post-CPB bleeding, an under-studied yet high-risk patient population.

Full description

Once the need for fibrinogen supplementation is confirmed, study participants will be randomized into one of two treatment groups (n=15 in each group):

1. Cryoprecipitate group (dose: 10 ml/kg; active control group) or
2. Fibrinogen Concentrate group (dose: 70 mg/kg; intervention group). There will be no placebo group since withholding treatment is neither consistent with standard of care nor acceptable ethically. No other aspects of care will be modified. In the event that an additional dose of fibrinogen supplementation is required (bleeding with documented hypofibrinogenemia) cryoprecipitate will be administered to all study subjects (including those who initially received FC).

Data to be obtained:

1. Demographic/preoperative data:

   • age in days/months (all participants to be 24 months of age or younger)
   • gender
   • weight
   • preoperative diagnosis
   • RACHS classification
   • surgery type & date (Norwood, arterial switch, truncus arteriosus, Glenn, anomalous pulmonary venous return, AV canal, tetralogy of Fallot, VSD closure, etc)
   • preoperative PT/INR/aPTT/hemoglobin level/ hematocrit/ platelet count/ WBC count/ fibrinogen level (Clauss method)
   • metabolic panel (sodium, BUN, creatinine, glucose, calcium, bicarbonate, Liver function tests)

2. Intra-operative Data:

   • CPB time & aortic cross clamp time
   • Use of hypothermic circulatory arrest (ice packs placed on the head)
   • ROTEM: Extem (CT/A10/A20/MCF) and Fibtem (A10/A20/MCF) at the following time points: baseline (after induction of anesthesia), 20 min prior to separation from CPB and 10 minutes after completion of fibrinogen concentrate/cryoprecipitate administration
   • Platelet count prior to separation from CPB
   • was ATIII administered? (thrombate)
   • Transfusion requirements: PRBC/Cell Saver/FFP/PLT/ cryoprecipitate - to be collected as number of units per each product, not volume. (for PLT - was it pooled PLT or single donor apheresis)
   • was rFVIIa given (factor seven, novoseven).
   • Need for ECMO support after separation trial from CPB
   • Was the chest left open?

3. Postoperative Data

   • PT/aPTT/INR/platelet count/ fibrinogen level/ Hgb level/HCT level on admission to the ICU
   • ROTEM parameters
   • Liver and kidney function tests on admission to the ICU
   • Bleeding (Chest drain output until 48 hours after surgery)
   • Need for additional transfusion (RBC/FFP/platelets/cryoprecipitate) until 7 days after surgery.
   • Factor VIIa administration
   • re-exploration for bleeding/tamponade (need for postoperative chest re-exploration or re- operation either in the ICU or in the OR due to excessive postoperative bleeding and/or cardiac tamponade)
   • Need for initiation of ECMO support in the ICU postoperatively
   • Duration of postoperative intubation
   • AKI (AKIN criteria)
   • Stroke/seizures > 24 hours post-operatively
   • Infection (sternal wound infection/mediastinitis/pneumonia/sepsis)
   • Thromboembolic complications (shunt thrombosis/DVT/PE)
   • ICU length of stay
   • Hospital length of stay
   • In hospital mortality

Enrollment: 30 patients

Sex: All

Ages: Under 24 months old

Volunteers: No Healthy Volunteers

Inclusion criteria

• pediatric (age 24 months or younger) patients undergoing elective cardiac surgery with CPB (n=30) in-whom fibrinogen supplementation after separation from CPB is indicated, based on the presence of clinically-significant bleeding and documentation of low fibrinogen level on viscoelastic point-of-care testing (MCF < 10 mm on the FIBTEM assay of ROTEM).

Exclusion criteria

• gestational age < 33 weeks at birth
• gestational age < 35 weeks on the day of surgery
• emergency surgery
• patient or parent history of coagulopathy/clotting abnormalities
• patient history of thrombophilia
• refusal to participate in the study,
• known severe allergic reaction/anaphylaxis to fibrinogen concentrate,
• administration of fibrinogen concentrate or cryoprecipitate in the 24 hours prior to surgery
• baseline fibrinogen level higher than 300 mg/dL (to avoid the risk of increasing the fibrinogen level above the normal upper level of 400 mg/dL)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

30 participants in 2 patient groups

Fibrinogen Concentrate

Experimental group

Description:

Fibrinogen Concentrate (dose: 70 mg/kg; intervention group). in-whom fibrinogen supplementation after separation from CPB is indicated, based on the presence of clinically-significant bleeding and documentation of low fibrinogen level on viscoelastic point-of-care testing (MCF \< 10 mm on the FIBTEM assay of ROTEM).

Treatment:

Drug: Fibrinogen

Cryoprecipitate

Active Comparator group

Description:

. Cryoprecipitate (dose: 10 ml/kg; active control group) in-whom fibrinogen supplementation after separation from CPB is indicated, based on the presence of clinically-significant bleeding and documentation of low fibrinogen level on viscoelastic point-of-care testing (MCF \< 10 mm on the FIBTEM assay of ROTEM).

Treatment:

Drug: Cryoprecipitate